A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
Sponsor: Tetra Discovery Partners
A PHASE3 clinical study on Fragile X Syndrome, this trial is completed. The trial is conducted by Tetra Discovery Partners and has accumulated 14 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE3
▶ Show 9 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Jul 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tetra Discovery Partners
For direct contact, visit the study record on ClinicalTrials.gov .